You are on page 1of 15

Human Resource Management

HUMAN RESOURCE
MANAGEMENT

Project
SUBMITTED TO:

SIR .YASIR AFTAB FAROOQI


SUBMITTED BY:

Gulam Abbass 08011420-012


Group #2

MBA 2nd

UNIVERSITY OF
GUJRAT
Human Resource Management
Human Resource Management

History
Novartis pharmaceutical is established in 1996.The history of Novartis traces back to
three companies

➢ Geigy Pharmaceutical
➢ Ciba pharmaceutical
➢ Sandoz pharmaceutical

Giegy whose origin goes back to the middle of the 18th century. CIBA founded around
1859and Sandoz established in 1886

In1970 CIBA and Giegy merged .the newly created CIBA-Geigy ltd and Sandoz
continued to follow separate path for two and half decades

In1996 Sandoz and CIBA-Geigy joined to form Novartis pharmaceutical.

Head Office

Novartis International AG
CH-4002 Basel
Switzerland
Tel: +41 61 324 11 11
Fax: +41 61 324 80 01

Head office in Pakistan


Novartis Pharma (Pakistan) LTD.
15 West Wharf Road, Karachi 74000, Sindh, Pakistan
Phone: 9221-2313389 / 2316286 / 2313387 / 2313390
Fax: 9221-2310241
Human Resource Management

Mission:
We want to discover, develop and successfully market innovative products to prevent
and cure diseases, to ease suffering and to enhance the quality of life.
We also want to provide a shareholder return that reflects outstanding performance and
to adequately reward those who invest ideas and work in our company.

Vision:
We want to discover, develop and successfully market innovative products to prevent
and cure diseases, to ease suffering and to enhance the quality of life. We also want to
provide a shareholder return that reflects outstanding performance and to adequately
reward those who invest ideas and work in our company.

Sector Head
Farhan Baider Malik
15 West Wharf Road, Karachi 74000, Sindh, Pakistan
Phone: 9221-2313389 / 2316286 / 2313387 / 2313390
Fax: 9221-2310241

Managers
Khalid Ashraf (National Sales Manager)

Moiz Haider (Brand Manager)

Zubair Ahmed (Training Manager)

Ali Imran (Human Resource Manager)

Moin Khan (Factory head)

Regional Sales Managers


Tuyyab Nazir Lahore
Mujeeb Alam Multan
M Shakeel Karachi
Human Resource Management

Arshad Iqbal Islamabad

Zonal Sales Managers


Lahore
Muhammad Zeeshan Altaf
M. Sohail Aslam

Faisalabad
M. Ejaz
Qamer Shahzad Ali

Islamabad
Naveed Basheer
Ikram Ulah Khan
M.Usman

Multan
Shahzad Jamil
Ghazanfar Aziz Ghauri
Qamar Zaman

Gujranwala
Abaid ur Rehman

Sukhar
Imtiaz Soomro
Abdul Hameed

Karachi
Faizan Ur Rehman
Syed Ather Hussain
Asif Ali Khan
Human Resource Management

Hyderabad
Jawaid Jabbar
Syed Shoaib Hussain
Naveed Farooque

Peshawar
Noorullah Jan
Inayat Ullah Khan Afridi

Designation of contacted person

Ali Imran
ACCA, MBA (HRM)

(Human Resource Manager)

Phone: 9221-2313388 / 2316289

Fax: 9221-2310242
Human Resource Management

Company Competitors
Human Resource Management

PRODECTS
➢ CAC-1000
➢ CAC 1000 Plus
➢ CAC 1000 Plus Pineapple
➢ VEG 20mg
➢ T DAY
➢ SPASMO CIBALGIN
➢ CALCIUM SAN. SYP.120ML
➢ TRIAMINIC SYP. 60ML
➢ TRIAMINIC SYP. 120ML
➢ TRIAMINIC-E SYP. 60ML
➢ TRIAMINIC-DM 60ML
➢ Triaminic Cold & Allergy
➢ Triaminic Cough
➢ Triaminic Chest Congestion
➢ Triaminic Cough, Cold & Fever
➢ TANDEGYL D
➢ TANDEGYL SYRUP
➢ NEO-INTESTOPAN 60 ml
➢ QALSAN MINT
➢ QALSAN MIX
➢ CALCIUM+VIT. C A50X10ML
➢ SANCOS
➢ TANDEGYL T-30
➢ TANDEGYL-DS T-10
➢ TANDEGYL INJ. A50X2ML
➢ LAMISIL CREAM
➢ LAMISIL SPRAY
Human Resource Management

➢ NEO-INTESTOPAN T 250
➢ OPTALIDON T-200

SWOT ANALYSIS

Strengths Weaknesses

• Market Leader • Only one formulation is available


• Strong CNS image of Novartis • No formulation for children
• Strong brand image-Heritage, Valuation • Mostly under dosage is recommended
• Strong rapport with KOLs • Lack of resources to tap attractive
• High acceptance of carbamazepine as opportunities
an anti epileptic
• FDA approved
• Effective in multiple indications
• First line, first choice therapy

Opportunities Threats

• High growth rate of the market • High SoV of competition


• More doctors particularly GPs are • Increasingly high acceptance of
diagnosing epilepsy valproates
• High treatment gap • Increased penetration of low cost
• Lot of potential in different indications Generics in institutions
(PDN) • Epival has many galenical forms
Human Resource Management

• New Molecules are high cost & with • Introduction of new molecules
low safety profile • Compliance is low

Weaknesses
WEAKNESSES
AND • Only one formulation is available
• No formulation for children
THREATS • Mostly under dosage is recommended
• Lack of resources to tap attractive
opportunities

Threats Proposed Strategies

• Existing Threat: High Share of Voice 1. Formulation should be


of competition. introduced for children and
• Increased penetration of low cost young adults.
Generics in institutions 2. Promotional Strategy to create
• Rapid growth of below the line and awareness and increase mind
direct to consumer advertising share
• Increasingly high acceptance of 3. Promote KOLs to increase the
valproates number of patients
• Epival has many galenical forms 4. Optimize the loyalty base of
• Potential Threat: Introduction of new Tegral users
molecules 5. Switch Epival users to Tegral
• Compliance is low 6. Low dosage range extension
Human Resource Management

• Entry/exit into the Industry: Increase should be introduced


in number of neuroscience competitive 7. In regions other than Karachi,
products. Consumers have been offered more Lahore and Peshawar,
and more choices. distribution should be made
more extensive to increase
availability. More agents should
be contacted
8. Management should strategize
their aims to retain their sales
force through benefit planning
and incentives.

Weaknesses
WEAKNESSES
AND • Only one formulation is available
• No formulation for children
OPPURTUNITIES • Mostly under dosage is recommended
• Lack of resources to tap attractive
opportunities

Opportunities Proposed Strategies


• Conduct seminars and workshops to
train GPs about Epilepsy and the usage
of Tegral.
• High growth rate of the market
• Treatment gap should be reduced by
• More doctors particularly GPs are
awareness programs in rural areas.
diagnosing epilepsy
• Cost - plus pricing should be practiced
• High treatment gap
for new molecules exposures and
• Lot of potential in different indications
regulations for safety should be
Human Resource Management

(PDN) enhanced
• New Molecules are high cost & with • Local firms desirous of export but
low safety profile lacking necessary export structure

Strengths

STRENGTHS
• Market Leader

AND •
Strong CNS image of Novartis
Strong brand image-Heritage, Valuation
• Strong rapport with KOLs
OPPURTUNITIES • High acceptance of carbamazepine as
an anti epileptic
• FDA approved
• Effective in multiple indications
• First line, first choice therapy
Human Resource Management

Proposed Strategies
Opportunities • Capitalize on strong CNS franchise –
build further rapport with KOLs
• Patient Evaluation Programs: For KOL
Development
• KEEP (Key Experts Evaluation
• High growth rate of the market Programs)- Painful Diabetic
• More doctors particularly GPs are Neuropathies for 30
diagnosing epilepsy Physicians
• High treatment gap •
BOC - 2 Programs for 30 Doctors each
• Lot of potential in different indications for PDN
(PDN) •
Epilepsy Project
• New Molecules are high cost & with
low safety profile - CME Programs for Family Physicians
(Epilepsy)

- Epilepsy Camps (28 camps organized so far)

• Neuroscience Summit: Patient


Evaluation Program for major Brands
of Neuroscience, Total 35 Top KOLs
from Neurology & Psychiatry

Strengths

• Market Leader
STRENGTHS •

Strong CNS image of Novartis
Strong brand image-Heritage, Valuation
• Strong rapport with KOLs
AND • High acceptance of carbamazepine as
an anti epileptic
• FDA approved
THREATS • Effective in multiple indications
• First line, first choice therapy
Human Resource Management

Threats Proposed Strategies


• Existing Threat: High Share of Voice • Build further rapport with KOLs
of competition. • Exploit on strong CNS franchise
• Increased penetration of low cost • Patient Evaluation Programs should be
Generics in institutions conducted for KOL Development
• Rapid growth of below the line and • Own distribution structure of Tegral,
direct to consumer advertising measuring highest in clinical
• Increasingly high acceptance of evaluation, effectiveness & safety
valproates • Summits of KOLs for top brands in
• Epival has many galenical forms neuroscience to increase share of voice
• Potential Threat: Introduction of new • Focus to minimize substitution.
molecules • More Focus on RMOS
• Compliance is low • Better Awareness of Epilepsy Project
• Entry/exit into the Industry: Increase • Refine Advertisement media
in number of neuroscience competitive • More sustained branding
products. Consumers have been offered • Powerful message delivery
more and more choices. • Monitor promotion in different
indications

Suggestions
➢ They should provide proper training to employees so that they can easily
understand the current technology.
➢ They should organize some seminars.
➢ HR should interact with labor as well as office staff.
➢ HR should look after the problems of each employee and try to solve according
his own experience.
➢ They should provide some extra facilities such as bonuses, increments, visits to
outside country so that they don’t think switch off.
Human Resource Management

➢ HR should develop ethical practices. For this purpose they should set some rules
and regulations.
➢ Right person for the right job.
➢ Looking for better ways of working after results in new ways of doing things.
➢ HR manager must be prepared to train employees in the new process and help
them train new level that may be associated with the “new. Improved”
operations.

Related Interests